more

McKesson (MCK)

(Delayed Data from NYSE)

$607.51 USD

+58.20 (10.60%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $604.00 -3.51 (-0.58%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum B VGM

Industry Rank:

Top 22% (54 out of 251)

Industry: Medical - Dental Supplies

View All Zacks #1 Ranked Stocks

Zacks News

Surging Earnings Estimates Signal Upside for McKesson (MCK) Stock

by Zacks Equity Research Published on November 08,2021

McKesson (MCK) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

MCKPositive Net Change

McKesson (MCK) Hits 52-Week High, Can the Run Continue?

by Zacks Equity Research Published on November 04,2021

McKesson (MCK) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

MCKPositive Net Change

McKesson (MCK) Earnings and Revenues Beat Estimates in Q2

by Zacks Equity Research Published on November 02,2021

McKesson's (MCK) fiscal second-quarter 2022 results benefit from substantial growth in the Medical-Surgical Solutions business.

medical-devices

McKesson (MCK) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research Published on November 01,2021

McKesson (MCK) delivered earnings and revenue surprises of 31.69% and 6.07%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

MCKPositive Net Change

Analysts Estimate McKesson (MCK) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research Published on October 25,2021

McKesson (MCK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MCKPositive Net Change

McKesson (MCK) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research Published on October 25,2021

McKesson's (MCK) fiscal second-quarter results are likely to reflect the solid show by the U.S. Pharmaceutical and Specialty Solutions segment.

Veeva Systems' (VEEV) eConsent Solution Gets Adopted by Celerion

by Zacks Equity Research Published on October 08,2021

Veeva Systems' (VEEV) solution gets adopted by Celerion in a bid to boost paperless clinical trials.

Here's Why You Should Add STERIS (STE) to Your Portfolio

by Zacks Equity Research Published on October 08,2021

Investors are optimistic about STERIS (STE) owing to elevated consumer demand and rebound in procedure volumes and raised 2022 outlook.

Here's Why You Should Retain Integer Holdings (ITGR) Stock Now

by Zacks Equity Research Published on October 07,2021

Integer Holdings (ITGR) continues to gain traction from portfolio management. However, intense competition is a woe.

Hill-Rom (HRC) New LT Strategy Aids, Y/Y Comparisons Ail

by Zacks Equity Research Published on October 06,2021

Hill-Rom's (HRC) newly initiated long-term growth strategies through fiscal 2022, focusing on all four strategic priorities, look attractive at this moment.

Omnicell (OMCL) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research Published on October 06,2021

Omnicell (OMCL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Here's Why You Should Retain Haemonetics (HAE) Stock for Now

by Zacks Equity Research Published on October 06,2021

Investors are optimistic about Haemonetics (HAE) on strong demand for NexSys PCS system and potential of Hemostasis Management franchise.